Fore Biotherapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3675 Market St Ste 200, Philadelphia, Pe...Phone Number
(267) 641-7575Website
fore.bioRevenue
$10.6 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Fore Biotherapeutics
Fore Biotherapeutics is a virtual biotechnology company focused on precision oncology treatments for patients with hard-to-treat cancers, specifically targeting unaddressed mutations in established oncology pathways. Their lead program, Plixorafenib, is an investigational BRAF inhibitor designed to target a range of BRAF gene alterations in cancer cells. The company is committed to delivering high-impact therapies with speed and quality, currently conducting a phase 2 clinical trial for patients with advanced solid tumors harboring BRAF alterations. With a team of exceptional talent across the USA, Fore Biotherapeutics aims to fulfill the promise of targeted therapy through innovative research and development.Explore more
Fore Biotherapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Fore Biotherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Fore Biotherapeutics is spiking on competitors!
Product Launch: Get notified when Fore Biotherapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Fore Biotherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Fore Biotherapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Fore Biotherapeutics
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Fore Biotherapeutics has new funding data
Earning: See what the market has to say on Fore Biotherapeutics recently announced quarterly report
Click to see if Fore Biotherapeutics had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Fore Biotherapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Fore Biotherapeutics
Compare insights from companies similar to Fore Biotherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Fore Biotherapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Fore Biotherapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Fore Biotherapeutics.
Fore Biotherapeutics financials insights
Gather financial insights about Fore Biotherapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$10M
2016
Private Equity
$2.5M
2018
Series B
$18.5M
2020
Series C
$57M
2026
Series D
$180.4M
Fore Biotherapeutics Tech Stack
A closer look at the technologies used by Fore Biotherapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
Fore Biotherapeutics News & Media
FORE Biotherapeutics to Participate in the Jefferies Global Healthcare Conference
PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today announced that the Company will participate in the Jefferies Global Healthcare Conference on Tuesday, June 3, 2025 in New York. William Hinshaw, Chief Executive Officer, and Michael Byrnes, Chief Financial Officer, will host and participate in one-on-one meetings. Please contact your Jefferies salesperson or Argot PartnFore Biotherapeutics Raises $38M in Series D-2 Financing
Fore Biotherapeutics, a Philadelphia, PA-based registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, raised $38M ion Series D-2 financing. Backers included R One, Medicxi, OrbiMed, HBM Healthcare Investments, Wellington Management, Novartis Venture Fund, Cormorant Asset Management, and 3B Future Health Fund. The company intends to use the funds to […] The post Fore Biotherapeutics Raises $38M in Series D-2 Financing appeared first onFORE Biotherapeutics to Present Plixorafenib Abstract at the 2025 American Society of Clinical Oncology Annual Meeting
PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today announced that a plixorafenib abstract has been selected for poster presentation at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO), taking place May 30-June 3, 2025 in Chicago. At ASCO 2025, Karisa Schreck, M.D., Ph.D., from the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University,
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Fore Biotherapeutics
Sign Up For FreeTo access detailed company insights
Fore Biotherapeutics is a virtual biotechnology company focused on precision oncology treatments for patients with hard-to-treat cancers, specifically targeting unaddressed mutations in established oncology pathways. Their lead program, Plixorafenib, is an investigational BRAF inhibitor designed to target a range of BRAF gene alterations in cancer... Read More
